Adenoscan

This page contains recent news articles, when available, and an overview of Adenoscan but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.


Overview:

Adenoscan
(when available)

Pharmacology and use:
Adenosine is an endogenous nucleoside occurring in all cells of the body and is not chemically related to other antiarrhythmic drugs. Adenosine is indicated for the conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). Adenosine is antagonized competitively by methylxanthines such as caffeine and theophylline, and potentiated by blockers of nucleoside transport such as dipyridamole. Adenosine is not blocked by atropine. For the conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome)

Mechanism Of Action:
Adenosine slows conduction time through the A-V node, can interrupt the reentry pathways through the A-V node, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome.

News Articles on Adenosine

King Pharmaceuticals Reports Second Quarter 2009 Financial Results  -  ‎Aug 6, 2009‎
Royalty revenues, derived primarily from ADENOSCAN(R) (adenosine), totaled $15 million during the second quarter of 2009. King management will conduct a FOXBusiness

Astellas to Terminate Offer for CV Therapeutics  -  18 Mar 2009
Some of Astellas' core products in the US are: Lexiscan(R) (regadenoson) and Adenoscan(R) (adenosine injection), pharmacologic stress agents indicated for FOXBusiness

King Pharmaceuticals, Inc. Q4 2008 Earnings Call Transcript  -  ‎Feb 26, 2009‎
...our second generation pharmacologic stress imaging agent that is intended to provide a reduced side effect profile compared to Adenoscan, which was also Seeking Alpha

News > Unternehmensnachrichten > Astellas Commences Tender Offer ...  -  ‎Feb 27, 2009‎
Some of Astellas? core products in the US are: Lexiscan ® (regadenoson) and Adenoscan ® (adenosine injection), pharmacologic stress agents indicated for Ad-Hoc-News (Pressemitteilung)

BUYINS.NET: (CVTX) SqueezeTrigger Price is $17.058. There is ...  -  ‎Mar 12, 2009‎
The study met its primary endpoint by showing that MPI studies conducted with regadenoson were comparable to MPI studies conducted with Adenoscan. Trading Markets (press release)

Astellas to Nominate Two Directors and Submit Proposal to Remove ...  -  ‎Mar 6, 2009‎
Some of Astellas’ core products in the US are: Lexiscan ® (regadenoson) and Adenoscan ® (adenosine injection), pharmacologic stress agents indicated for Earthtimes (press release)

Astellas Proposes to Acquire CV Therapeutics for $16 Per Share in Cash  -  Jan 27, 2009
Some of Astellas’ core products in the US are: Lexiscan ® (regadenoson) and Adenoscan ® (adenosine injection), pharmacologic stress agents indicated for WELT ONLINE,

Clinical Data, Inc. Reports Advances in Two Late-Stage Therapeutic ...  -  Jan 12, 2009
...imaging demonstrated comparable diagnostic accuracy and an improved adverse event profile, when compared to an existing agent, Adenoscan (adenosine). PR-Inside.com (Pressemitteilung),

King Pharma swings to profit in Q3 on lower charges, despite ...  -  Nov 6, 2008
...from $48 million in the year-ago quarter, while Royalty revenues totaled $18 million, down from $20 million last year, derived primarily from Adenoscan. RTT News,

King Pharmaceuticals Inc. Q3 2008 Earnings Call Transcript  -  Nov 7, 2008
Total revenues during the quarter also include $68 million from our Meridian Auto-Injector business and Adenoscan royalties of $18 million. Seeking Alpha,

King Pharmaceuticals Reports Third-Quarter 2008 Financial Results  -  Nov 6, 2008
Royalty revenues, derived primarily from ADENOSCAN ® (adenosine), totaled $18 million during the third quarter ended September 30, 2008, compared to $20 istockAnalyst.com (press release),

Myocardial Sympathetic Innervation in Patients With Symptomatic ...  -  Sep 24, 2008
Pharmacologic stress was performed with adenosine (Adenoscan; Sanofi-Aventis GmbH) (0.14 mg/kg/min) over 6 min. Blood pressure (mm Hg) was monitored during RedOrbit,

Holy Moley, CV Therapeutics!  -  Aug 1, 2008
Especially given the strong competition from King Pharmaceuticals (NYSE: KG) and Astellas' similar imaging agent, Adenoscan, these swift and lucrative Motley Fool

CV Therapeutics announces strong sales for imaging agent  -  Aug 4, 2008
...of active marketing in June despite strong competition from King Pharmaceuticals and Astellas, which sell a similar imaging agent called Adenoscan. SmartBrief,

Astellas launches Lexiscan (TM) (Regadenoson) injection for use as ...  -  02 Jul 2008
...with 95 per cent confidence that MPI studies conducted with Lexiscan were similar to MPI studies conducted with Adenoscan® (adenosine injection). Medicexchange,

Selective adenosine-receptor agonist for resting perfusion scans ...  -  Jun 24, 2008
Unlike Adenoscan, Lexiscan is administered as a non-weight-adjusted rapid IV bolus; Astellas says that its adenosine-receptor selectivity should give the TheHeart.Org,

Williams-Labadie Wins In-Awe 2008 Silver Award!  -  Jun 25, 2008
The award was received in the category of “Print – Professional and Trade Journal Advertising� for the Adenoscan® (adenosine injection) campaign produced by Business Wire (press release),

Williams-Labadie Appoints Senior  -  Jun 19, 2008
Frank will be responsible for the Astellas business, supervising the Adenoscan and Lexiscan promotional accounts. Prior to joining Williams-Labadie, Ad-Hoc-News (Pressemitteilung),

King Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript  -  May 8, 2008
Our total revenues during the first quarter also include $43 million from our Meridian Auto-Injector business and Adenoscan scan royalties of $19 million. Seeking Alpha,

King Pharmaceuticals Reports First-Quarter 2008 Financial Results  -  May 8, 2008
Royalty revenues, derived primarily from ADENOSCAN ® (adenosine), totaled $19 million during the first quarter ended March 31, 2008. Business Wire (press release),

CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM ...  -  Apr 10, 2008
Astellas currently markets Adenoscan(R) (adenosine injection), the leading pharmacologic stress agent for MPI studies in the United States. FOXBusiness

A Little Delay Goes Away for CVT  -  Apr 14, 2008
The company is an ideal marketing partner for regadenoson because it also markets King Pharmaceuticals' (NYSE: KG) Adenoscan, which regadenoson was tested Motley Fool

CV Therapeutics Banks $175M in Royalties Deal for Lexiscan  -  Apr 16, 2008
Arguments can be made that Lexiscan has some convenience, safety and tolerability benefits over Astellas' Adenoscan (adenosine injection), TMCnet

CV Therapeutics, Astellas Heart-Monitor Drug Approved (Update1)  -  Apr 10, 2008
Regadenoson was designed to work faster and pose fewer side effects than the leading drug now used in cardiac stress tests, Astellas's Adenoscan. Bloomberg

Adenosine agonist for stress perfusion imaging approved  -  Apr 15, 2008
...perfusion scans of similar quality to those made using another Astellas product, adenosine injection (Adenoscan), according to the announcement. TheHeart.Org,

Williams-Labadie Appoints New Account Service Manager  -  Apr 15, 2008
...announced today the appointment of Carly Gill to Account Service Manager for Astellas' Adenoscan account, reporting to Susan Fennema, Director, Centre Daily Times,

CV, Astellas gain Leixscan approval  -  Apr 11, 2008
It works faster and has fewer side effects that Astellas' Adenoscan, the current market leader. "We are extremely pleased that the FDA has approved Lexiscan FierceBiotech,

FDA Okays Regadenoson (Lexiscan) as Pharmacologic Stress Agent  -  Apr 11, 2008
In two phase III trials with a total of 2015 patients, regadenoson had stress scan agreement rates similar to those with adenosine (Adenoscan) injection, MedPage Today,

CVT's Copacetic Cash Management  -  Apr 17, 2008
Astellas also markets Lexiscan's primary competition, Adenoscan, which brought in 40 billion yen (more than $390 million at today's exchange rates) in North Motley Fool

Aerojet Receives NASA Liquid Oxygen-Liquid Methane Engine ...  -  Apr 10, 2008
...for scan agreement rates by showing with 95% confidence that MPI studies conducted with Lexiscan were similar to MPI studies conducted with Adenoscan. RTT News,

King Pharma Q4 Net Income Increases; EPS, Revenue Top Street ...  -  Feb 28, 2008
Royalty revenues, derived primarily from ADENOSCAN totaled $22 million during the quarter. For fiscal 2007, the company reported net income of $182.98 Trading Markets (press release),

King Pharmaceuticals Reports Year-End and Fourth-Quarter 2007 ...  -  Feb 28, 2008
Royalty revenues, derived primarily from ADENOSCAN(R) (adenosine), totaled $22 million during the fourth quarter of 2007 and $83 million for the year ended Centre Daily Times,

Adenoscan(R) Patent Lawsuits Settled  -  Oct 22, 2007
Under the terms of the settlement agreement, Teva will be able to launch their generic version of Adenoscan pursuant to a license in September 2012, CNNMoney.com

Teva to Market Generic Adenoscan Three Years Early  -  Oct 29, 2007
Teva Pharmaceutical Industries will be able to launch generic Adenoscan under license in September 2012 as part of a settlement agreement with Astellas FDA news (subscription),

Settlement lets Teva sell stress test drug  -  Oct 22, 2007
The settlement allows for Teva to start selling Adenoscan in September 2012 or earlier under certain conditions. Additional terms of the settlement were not Bizjournals.com,

Astellas Pharma, King Pharma settle lawsuits against Teva  -  Oct 22, 2007
N: Quote, Profile, Research) had settled lawsuits against Teva Pharmaceutical related to Adenoscan, an agent used in heart stress study. Reuters

Market Report -- In Play (TEVA)  -  Oct 22, 2007
Teva Pharm announces that Adenoscan patent lawsuits settled Astellas Pharma, King Pharmaceuticals (KG) and Teva Pharmaceutical Industries (TEVA) announce MSN Money

Merrill Lynch: Teva will beat estimates  -  Oct 22, 2007
Under the settlement agreement, Teva will be able to launch its generic version of Adenoscan pursuant to a license in September 2012, or earlier under Globes,

King Pharmaceuticals Reports Third-Quarter 2007 Financial Results  -  Nov 8, 2007
Royalty revenues, derived primarily from ADENOSCAN(R) (adenosine), totaled $20 million during the third quarter ended September 30, 2007. PharmaLive.com (press release),

Indevus Appoints Industry Veteran Kurt Lewis as Senior Vice ...  -  Jun 29, 2007
CNNMoney.com...and marketing positions and successfully led the growth of multiple products into market leaders including Prograf(R), Adenoscan(R) and AmBisome(R).

CV Therapeutics Submits New Drug Application For Regadenoson  -  May 15, 2007
PipelineReview.com (press release),All study participants received a clinically indicated baseline MPI study using Adenoscan(R) (adenosine injection). Participants then were randomized to

Astellas Terminates Agreement on Acute Heart Failure Agent Carperitide  -  Jan 11, 2007
PharmaLive.com (press release),...and the marketing of such products as Adenoscan®, a pharmacologic stress agent in pharmaceutical stress testing; Vaprisol® for euvolemic hyponatremia;

Regadenoson Meets Primary Endpoint in Second Phaase 3 Clinical Trial  -  Dec 5, 2006
PipelineReview.com (press release),All study participants received a clinically indicated baseline MPI study using Adenoscan(R) (adenosine injection). Participants then were randomized in a

CV Therapeutics shares rise on heart agent news  -  Dec 4, 2006
ReutersThe study compared the agent, regadenoson, with a current injectible agent called Adenoscan in patients undergoing a heart stress test called myocardial

CV Therapeutics Agent Does Well in Trail  -  Dec 4, 2006
Forbes,CV Therapeutics (nasdaq: CVTX - news - people ) said in late-stage trials regadenoson was comparable to Adenoscan, another drug used in MPI studies.

CV Therapeutics Agent Does Well in Trail  -  Dec 4, 2006
Houston Chronicle,CV Therapeutics said in late-stage trials regadenoson was comparable to Adenoscan, another drug used in MPI studies. If regadenoson is approved by the FDA,

CV Therapeutics (CVTX) Said Regadenoson Met Primary Endpoint  -  Dec 4, 2006
StreetInsider.com (subscription),...with 95 percent confidence that MPI studies conducted with regadenoson were comparable to MPI studies conducted with Adenoscan (adenosine injection).

Genzyme Introduces New Genetic Test and Gilead Stock Jumps  -  Dec 5, 2006
Financial News USA (press release),CV Therapeutics said in late-stage trials regadenoson was comparable to Adenoscan, another drug used in MPI studies. Shares of biopharmaceutical company

CV Therapeutics cardiac drug meets study goal  -  Dec 4, 2006
Pharmaceutical Business Review...its primary endpoint by showing with 95% confidence that MPI studies conducted with regadenoson were comparable to MPI studies conducted with adenoscan.

King Pharmaceuticals Reports Third-Quarter 2006 Financial Results  09 Nov 2006
Royalty revenues, derived primarily from Adenoscan ® (adenosine), totaled $19 million during the third quarter ended September 30, 2006, compared to $22 ... -Business Wire (press release), King Pharmaceuticals reports 8% second quarter total revenues ...  Aug 9, 2006
Royalty revenues, derived primarily from Adenoscan(R) (adenosine), totaled $21 million during the second quarter ended June 30, 2006, compared to $20 million ... -Kingsport Times News



King Pharma Q1 Adj. EPS Beats Street Expectations; Revenues Climb ...  May 9, 2006
Royalty revenues, derived primarily from Adenoscan (adenosine), totaled $20 million during the first quarter ended March 31, 2006, compared to $18 million ... - Trading Markets

King Pharmaceuticals Reports First-Quarter 2006 Financial Results  May 9, 2006
Royalty revenues, derived primarily from Adenoscan(R) (adenosine), totaled $20 million during the first quarter ended March 31, 2006, compared to $18 million ... - PR Newswire



King Pharmaceuticals Reports Year-End and Fourth-Quarter 2005 ... Feb 28, 2006
Royalty revenues, derived primarily from Adenoscan(R) (adenosine), totaled $18.2 million during the fourth quarter and $78.1 million during the twelve months ... - PR Newswire,

'Tentative' FDA nod on Teva drug  Feb 13, 2006
On final approval, the injection will be the AP-rated generic equivalent of Astellas Adenoscan Injection, a product used as an supplement to thallium-201 ... - Jerusalem Post,

King Pharmaceuticals Reports Year-End and Fourth-Quarter 2005 ... Feb 28, 2006
Royalty revenues, derived primarily from Adenoscan® (adenosine), totaled $18.2 million during the fourth quarter and $78.1 million during the twelve months ... - Yahoo! News

Teva Announces Tentative Approval of Adenosine Injection  Feb 13, 2006
Upon final approval, Teva's Adenosine Injection will be the AP-rated generic equivalent of Astellas Adenoscan(R) Injection, a product indicated as an adjunct ... - Genetic Engineering News,

Williams-Labadie Promotes Jim Grossmann to Senior Vice President ...  Jan 13, 2006
During that time, he has directed a wide range of innovative marketing programs to support the growth of Adenoscan® -- the largest brand in the Astellas ... - PharmaLive.com

Brand Names/Synonyms:
Adenoscan is also known by the following brand names and/or synonyms2'-Deoxyadenosine; Adenine Deoxy Nucleoside; Adenine Deoxyribonucleoside; Adenine Deoxyribose; Adenine Nucleoside; Adenine Riboside; Adenocard; Adenocor; Adenoscan; Adenosin; Adenosine; Adenosine 99%; Adenosine for Biochemistry; Adenosine, Free Base; Adensoine; Adenyldeoxyriboside; Boniton; CCRIS 1782; Da; Deoxyadenosine; Desoxyadenosine; Myocol; Nucleocardyl; Sandesin; Usaf Cb-10

Drug Category:
Adenoscan is categorized under the following by the FDA: Vasodilator Agents; Antiarrhythmic Agents; Analgesics; Cardiac drugs; ATC:C01EB10

Dosage Forms:
LIQUID

Absorption:
Not Available

Interactions:
Interactions for Adenosine:

Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile. Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard. Because of the potential for additive or synergistic depressant effects on the SA and AV nodes, however, Adenocard should be used with caution in the presence of these agents. The use of Adenocard in patients receiving digitalis may be rarely associated with ventricular fibrillation.

The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline. In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective. Adenosine effects are potentiated by dipyridamole. Thus, smaller doses of adenosine may be effective in the presence of dipyridamole. Carbamazepine has been reported to increase the degree of heart block produced by other agents. As the primary effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine.





Chemical IUPAC Name:
2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol

:
 
Web health.mongabay.com/health


Health Home | Conditions | Cancer | Medications | Surgery | Vaccines

mongabay.com


Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com/health lead to other sites. health.mongabay.com/health does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com/health responsible for dead or misdirected links.

IF YOU NEED A LINK/TEXT REMOVED FROM THIS PAGE, PLEASE CONTACT: mongabay (at) gmail.com


COPYRIGHT 2007 MONGABAY.COM